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The selectivity inherent in single gene silencing by small interfer-
ing RNAs (siRNAs) carries great therapeutic potential [1,2]. There has
nonetheless been slow progress towards clinical application of siRNA
because of a number of limitations, including triggering of immune
responses by both viral vectors, and liposomal vehicles [3,4] and inef-
fective delivery of therapeutic concentrations to target cells resulting
from (for example) the inability of delivery systems to speciﬁcally se-
lect target cells from their surroundings [5]. All the in vivo therapeutic
approaches tested to date incorporate as their ﬁnal common pathwaythe extracellular space. This is a signiﬁcant limitation because the ex-
tracellular volume is large, leading to dilution. It is a space shared by
target cells and surrounding cells alike, which limits speciﬁcity and
presents the potential for immune interactions.
To avoid the issues inherent in delivery via the bloodstream or by
direct interstitial delivery, cells have been suggested as an alternative
delivery mechanism. It was recently speculated that this could be ac-
complished utilizing pinocytotic delivery of exosomes [6]. This ap-
proach, however, still involves the extracellular space.
An alternative is provided by gap junction channels [7] that avoids
the extracellular space bymoving siRNA from the interior of the deliv-
ery cell to the interior of the target cell through an intercellular chan-
nel. In this brief review, we ﬁrst describe the evidence for cell based
delivery of siRNA mediated by gap junction channels. We follow this
description with an evaluation of a pinocytotic-based pathway. Final-
ly, we describe a rationale for using adult mesenchymal stem cells
(MSCs) as the cell of choice for focal or systemic delivery of siRNA.
Fig. 1. Fig. 1A is a micrograph showing Cx43 in rat mesenchymal stem cells [5] at cell–
cell interfaces. Red = phalloidin staining, Green=Cx43, Blue = DAPI The insert is a
western blot showing robust expression of Cx43 and molecular markers, 50,40 and
30 kD, in the left lane. Fig. 1B shows a typical macroscopic record of junctional currents
taken at different voltages. Fig. 1C shows multichannel activity obtained from human
MSCs. Insert: horizontal bar=2 s, vertical bar=5 pA.
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Gap junction channels form intercellular conduits between adja-
cent cells exclusive of the extracellular space, allowing easy transfer
of solutes from one cell interior to another [8,9]. In mammals the con-
nexin is the predominant subunit protein that forms gap junction
channels. There are more than 20 identiﬁed connexins in the human
genome and the majority of human cell types express connexins, the
only notable exception being adult skeletal muscle. Many tissues
express multiple connexins [10]; as a result three generic channel
types are possible, homotypic, heteromeric and heterotypic [11–15].
Homotypic channels are composed solely of one type of connexin
while heteromeric and heterotypic channels incorporate at least two
connexin types. The literature is replete with examples of in vitro
homocellular coupling in which the pair is composed of two identical
cells [14–17] and in vitro heterocellular coupling, such as a stem cell
and a cardiac myocyte cell pairs, mediated by the formation of func-
tional gap junction channels [18,30]. In vivo evidence also demon-
strates heterocellular coupling, an example being endothelial cells
and vascular smooth muscle [19] and, in the extreme, xenographic
heterocellular coupling [20,21]. One essential feature for the forma-
tion of gap junction channels is close apposition of cells while a second
is the expression of cellular adhesion molecules like the cadherin
family of proteins [22]. The expression of adhesion molecules such
as cadherins is robust within all the tissues [23,24] and should be
assessed when considering the selection of delivery and target cells.
2.1. Essential properties for a cell based, gap junction mediated delivery
system
There are three necessities for an intercellular delivery system uti-
lizing gap junctions: (1) adequate expression of connexins to sustain
a sufﬁcient pool of active channels; (2) adequate patency or channel
open probability to facilitate rapid transfer; (3) sufﬁciently permis-
sive permeability/selectivity properties. Fig. 1A illustrates connexin
protein expression and distribution in the form of green ﬂuorescence
at cell boundaries and within perinuclear intracellular compartments.
The original studies that determined connexin turnover rate
by Fallon and Goodenough [25] revealed a half-life for connexin32
of 4–5 h. Subsequent studies have generated similar results for
other connexins including Cx43 [26,27]. Despite the rapid turnover
rate for connexins dual voltage clamp/dual whole cell patch clamp
has shown gap junction mediated coupling to be common to most
cell types [7,9,28–30] and has allowed the determination of open
probability and permeability of gap junction channels for the more
ubiquitously expressed connexins. By far the best example is Cx43
which is expressed robustly in many cell types [10]. Open probability
of homotypic Cx43 channels ranges from 0.5 to nearly 1.0 when
transjunctional voltage is small and the percentage of time occupied
by open subconducting states (lower than the maximal conductance
value) is less that 5% of the total open time [31,32]. Fig. 1B illustrates
symmetric voltage dependence typical of homotypic Cx43 and Fig. 1C
shows typical multichannel activity indicative of Cx43.
Using dual whole patch clamp, different monovalent cations and
anions can be introduced into a cell pair and their relative permeabil-
ity assessed. In general, gap junctions tend to be weakly selective for
monovalent cations over anions [29,33,34]. The cation sequence often
follows an Eisenmann series I or II sequence, suggesting a solvent en-
vironment within the pore similar to that in the bulk solution [35,36].
Recent studies by Mathias et al. [37] and Gao et al. [38] have modeled
and experimentally demonstrated bulk ﬂuid ﬂow through gap junc-
tion channels which is consistent with the Eisenmann series data,
and provides additional evidence that gap junction channels are a sol-
vent-ﬁlled space.
The type I or II sequence is most consistent with a poorly-selective
channel, but not all connexins are the same in this regard. Considerthat Cx43 has a lower unitary conductance than Cx40 or Cx37 but is
less selective for anions relative to cations. One possible explanation
is that Cx40 or Cx37 might have a lower access resistance but a smal-
ler pore diameter and/or a different distribution of ﬁxed charge sites
along some portion of their lengths [33,34,36,39].
Other tools useful in assessing the permeability and selectivity
characteristics of connexins are ﬂuorescent and radiolabeled probes
of larger size than monovalent cations and anions [40–43]. Studies
which use exogenous probes or monitor reporter gene activity [44]
resulting from transfer of endogenous solutes (e.g., second messen-
gers) into recipient cells, generally are consistent with a poorly selec-
tive channel type. A general rule which has emerged for all connexins
thus far studied is: Only when the minor diameter of the solute probe
begins to approximate the functional diameter of the pore wall does
selectivity in the form of size and charge affect solute/probe perme-
ability [43,44]. As previously mentioned the least selective gap junc-
tion channel is one composed of Cx43, whose properties make it the
most likely channel to allow the passage of large solutes. In 2005
Neijssen and collaborators [45] asked if a ﬂuorescently labeled poly-
peptide of up to 8 amino acids (~1.8 kD) in length could pass from
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morphologies: rod shape (minor diameter ~0.8nm) and spherically
shaped (diameter ~1.8 nm). The rod shaped form was permeable
while the spherical form was not. If channels are permeable to rod-
like polypeptides, could similarly sized siRNA or miRNA molecules
also diffuse through a gap junction channel? In fact, a number of lab-
oratories have shown that gap junction channels composed of Cx43
are permeable to siRNA and miRNA with minor diameters of~1.0
nm [7,46–49] and that delivery of siRNA/miRNA from a source cell
to a recipient cell, through Cx43 gap junctions can affect the function
of a target gene. Wolvetang et al., [46] have demonstrated gap junc-
tion mediated silencing of GFP in embryonic stem cells grown in cul-
ture. Their data further suggests that shRNA can be loaded into a
delivery cell and siRNA can be transferred via gap junctions. Kizana
et al., [47] have shown miRNA and siRNA transfer between heart
cells was able to suppress GFP and SERCA expression respectively.
To demonstrate that gap junctions were the preferred intercellular
pathway a dominant-negative mutant form of Cx43 was transfected
into a population of heart cells and no effective reduction of GFP
was seen in the target heart cells in co-culture. Katakowski et al.
[48] have shown silencing of the reporter gene luciferase in trans-
fected glioma cells and provide evidence that gap junctions mediated
the transfer by demonstrating a lack of silencing in the presence of
the gap junction uncoupler carbenoxolone. Lim et al., [49] have dem-
onstrated transfer of appropriate miRNAs targeting CXCL12 from
bone marrow stromal cells to breast cancer cells resulting in reduced
cell division in the breast cancer cells. One study by Valiunas et al., [7]
also demonstrated that not all connexins are alike with regard to
siRNA permeability. They showed that unlike Cx43-expressing cells,
cells co-expressing Cx26 and Cx32 were not able to pass sufﬁcient
siRNA to effectively silence a targeted gene, polymerase Beta. It re-
mains to be seen whether other gap junction channels can or cannot
pass siRNA. In human mesenchymal stem cells (hMSCs), both Cx43
and Cx40 are present. Although Cx43-based gap junction channels
appear to be the major channel detectable in multichannel recordings
of hMSCs, it is possible that Cx43/Cx40 heteromeric channels are also
present and are permeable to siRNA/miRNA. Fig. 2 depicts the general
scheme for Cx43 mediated transfer.
The aforementioned studies illustrate three essential observations
that indicate siRNA is delivered via gap junctions. First, siRNA transfer
did not occur when connexin-deﬁcient cells were used as a source of
siRNA in co-culture with cells expressing a target gene [7]. Second, it
was unambiguously demonstrated that the intercellular transfer of aCx43: pore diam
siRNA single strand: min
siRNA source cell
Fig. 2. Fig. 2 is a schematic showing siRNA delivery mediated by gap junctions where the sou
to permit constitutive generation of an siRNA. The limiting pore diameter is given as 1.1 nm
1.0 nm [7].ﬂuorescently tagged morpholino (a siRNA analog) declined with in-
creasing length, a property predicted for permeation through a chan-
nel [7]. Third, application of the gap junction channel uncouplers
carbenoxolone or octanol or dominate negative mutant forms of
Cx43 prevented transfer of the delivery molecule and as a result do
not affect the expression of reporter genes in target cells [48,49].
These observations, along with the ability of siRNA/miRNA to survive
within cells for many hours or days, suggests that a source cell might
be able to deliver sufﬁcient quantities of siRNA/miRNA to affect gene
expression many cell lengths away [5,50].
An additional question with regard to gap junction channels and
siRNA/miRNA permeability is whether or not hemichannels are per-
meable. Hemichannels are one-half of a complete intercellular chan-
nel and are inserted into the cell membrane away from the region
of close cell–cell apposition. Logic dictates that if large numbers of
hemichannels were functional then substantial siRNA/miRNA could
potentially be lost to the extracellular space. This possibility has not
yet been tested. Hemichannel open probability is low when extracel-
lular calcium is in the normal physiological (millimolar) range, but is
increased when Ca is dropped to micromolar levels. It remains to be
seen whether hemichannels have sufﬁcient open probability and per-
meability to siRNAs under the normal range of [Ca++]i and under
ionic conditions that mimic pathophysiological environments to be
an effective delivery pathway for siRNA/miRNA.
2.2. An alternative pathway: pinocytotic delivery
Cell to cell delivery mediated by pinocytotis is an obvious alterna-
tive pathway for the transfer of siRNA/miRNA from a source cell to a
target cell. Delivery of mutant superoxide dismutase-1 [51], is consis-
tent with the speculations by Gibbings and Voinnet [6] on the utility
of endosomal and exosomal cell to cell transport (Fig. 3).
Pinocytotic/exocytotic delivery route has a number of potential
rate limiting steps. First, will there be adequate loading of vesicles/en-
dosomes/exosomes or vesicles with siRNA/miRNA from within the
conﬁnes of the intracellular space. Second will siRNA loaded vesicles
(pinosomes) fuse with lysosomes? Third will the number of exocytot-
ic events be sufﬁcient to carry the necessary number of siRNA mole-
cules? Fourth what will be the concentration of siRNA released
directly into the extracellular medium or alternatively, if released via
exosomes, howmany such events are required? There are no data rel-
evant to the ﬁrst concern. While it is known that pinosomes will fuse
with lysosomes the extent to which a siRNA exosome or endocytosedeter=~1.1 nm
or diameter= ~1.0 nm
Target cell
rce of the delivery siRNA can be direct transfection of siRNA or the transfection of cDNA
for Cx43 [29,33,34]. The minor diameter for single stranded siRNAs is approximately
Fig. 3. Fig. 3 illustrates a cell pair with the proposed pinocytotic/exosomal routes. Only a small fraction of the siRNA/miRNA (dashed line) that exits the delivery cell enters the target
cell, whether extruded via direct exocytosis into the extracellular space or via an exosome, because of dilution in the large volume of the extracellular space.
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ﬁned. However, the third and fourth concerns can be evaluated quan-
titatively by considering the resting frequency of pinocytotic events
for a cell. The question, simply put, is how much intracellular volume
exchange occurs via pinocytosis and is this enough to deliver a sufﬁ-
cient number of siRNA molecules into an adjacent cell to be effective?
In non-secretory and secretory cells the basal vesicle fusion rate
has been assessed using cell-attached patch clamp to be ~1 event/min,
with an average capacitance of ~0.2 femtoFarads (fF) and vesicle
diameter of 100 nm. This occurs within the attached membrane of
5 μm2 with a total capacitance of ~50 fF [52,53]. Since the frequency
of events is 1/min and includes both endocytotic and exocytotic
events, then to replace the entire attached membrane surface area
would require 250 exocytotic events over 4.2 h or ~1430 events over
a 24 h period. The more important parameter to assess is the volume
exchange for the exocytotic events assuming the cell contains siRNA/
miRNA within its cytoplasm and other intracellular compartments.
For a single 100 nm vesicle the ratio of its volume to the total cell vol-
ume would be 5×10−19 L/2×10−12 L for a 20 um diameter cell. Thus
one vesicle is ~1 millionth of the cell volume. Over a 24 h period the
total number of events or occurrences over the entire cell surface is
~20× that of the attached patch which translates into ~28,000 events
with a total volume exchange of 1.4×10−14 L or 0.7% of the cell vol-
ume. Assuming the [siRNA] in the vesicles is equal to or less than
that of the cell cytoplasm the exocytosis would only deplete the
source concentration by roughly 0.7% over a 24 h period. In con-
trast, for gap junctions an oligonucleotide 22 bases long has been
shown to have a transfer rate of ~1–2% over 40 min[7]. For a 24 h
period the concentration in a target cell, of a cell pair, would ap-
proach equilibrium such that the siRNA source cell and target cell
would have approximately the same concentrations of siRNA.
This comparison alone makes pinocytosis/exosome delivery seem
less advantageous than a direct conduit between cells coupled by gap
junction channels. But another, potentially overwhelming, concern
must also be taken into account, the dilution induced by the extracel-
lular space which will further dilute solutes released by exocytosis by
at least an order of magnitude.
Exosomes, often rich in RNA including miRNAs, derived from a de-
livery cell in situ represent an alternate vesicle population that can be
released into the extracellular space with a membranous envelope.
The small vesicular structures (30–60 nm) appear to reenter cells
via endocytosis [54] and do not readily fuse with the plasmamembrane to empty their contents into the cytoplasm of a target
cell. Rather, they are endocytotically introduced to the cell interior.
Exosomes appear to collect large numbers of tetraspanins in their
membranes and these are believed to be involved in target speciﬁcity
for endothelial cells and perhaps others [55].
In vitro harvesting of siRNA-loaded exosomes and subsequent sys-
temic delivery is another approach by which siRNA could be delivered
to target cells [56,57]. Although exosomes can be engineered to ex-
press proteins to facilitate homing to a desired tissue, delivery is
still subject to dilution by the large volume of the extracellular
space. Further, exosomes are subject to packaging that would not
necessarily insure the incorporation of a speciﬁc siRNA into its
lumen [58]. Only one study by Lim et al., [49] has attempted to assess
exosomal delivery to target cells and found it to be signiﬁcantly less
efﬁcient than gap junction mediated delivery of equivalent miRNAs.
A ﬁnal point is the fate of materials delivered into a cell via vesi-
cles,endosomes, exosomes. These organelles can become incorporat-
ed into lysosomes [6] which would further diminish the efﬁcacy of
such a delivery system.3. Cell based delivery: cell types of choice for in vivo delivery
3.1. The advantages
Cell based delivery has as its ﬁrst requirement the recognition as
“self” in vivo to avoid an immune response. Immune privilege is a
property of the mesenchymal stem cell thus allowing allogenic as
well as autologous use. Mesenchymal stem cells have also been
shown to be transfectable via nucleoporation and to remain stably
transfected [18,20]. Focal delivery via catheters can be used to intro-
duce a relatively large number of cells within a target tissue [18]
and large numbers of hMSCs can also be seeded onto various mate-
rials and surgically placed into an organ and subsequently become in-
tegrated into the target tissue and modulate function [59]. Moreover,
stem cells can home to particular sites when delivered systemically.
For example, Khakoo et al. [60] provided indirect evidence that
MSCs home to a tumor site. In addition Potapova et al., [61] have
demonstrated that hMSCs after expansion in vitro can be induced to
express CXCR4 receptors, an essential element of homing. Finally,
wild-type hMSCs express both Cx43 and Cx40 and form siRNA per-
meant gap junction channels [7,30].
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Delivery of stem cells whether localized or systemic does not
guarantee that the cells will remain at the injection site, and with sys-
temic delivery the question of whether they will even arrive in sufﬁ-
cient numbers is a consideration. Also even if success in delivery is
achieved whether these multipotent stem cells will differentiate
once present within a tissue remains to be seen.
4. Conclusions
SiRNA has great therapeutic potential because of its function to si-
lence expression of speciﬁc proteins [62]. However, the ability to tar-
get exogenous siRNAs to particular locations in vivo and deliver them
intact to the interior of target cells has been problematic [3,4,63]. For
this reason we have considered a cell based siRNA delivery system
using human mesenchymal stem cells. HMSCs do not invoke an
immune response [64] and are able to readily express permeant con-
nexins (Cx43 and Cx40) and couple both to homocellular and hetero-
cellular target cells in vitro and in vivo [20,30].
Cx43 is expressed in many organs: a few examples include the
heart, vascular wall [10] and within the muscularis externa and enter-
ocyte lining of the small intestine [65] and alveolar epithelium [66].
As a consequence, cellular delivery of speciﬁc siRNAs via Cx43 based
gap junction channels has the potential to signiﬁcantly alter disease
states such as cardiac arrhythmia, hypertension, and cancer. An ex-
ample of the latter is neoplastic bone tissue that expresses Cx43 [67].
Pinocytotic delivery of siRNA is another potential delivery path-
way but the efﬁcacy of such a system has yet to be demonstrated.
Endocytosis of naked siRNA, tagged siRNA or an exosome also has
the possibility of triggering activation of the TLR7 receptor pathway,
possibly resulting in an immune response [68], a problem not
expected to affect cell based delivery via gap junctions by an immune-
privileged cell.
Thus our conclusion at present, is that the autologous/allogenic
use of hMSCs to directly deliver siRNA from a source cell to a target
cell exclusive of the extracellular space represents the most promis-
ing in vivo cell based delivery system and may have the potential
therapeutic applications.
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